Ponikowski, Piotr; Kirwan, Bridget-Anne; Anker, Stefan D.; Dorobantu, Maria; Drozdz, Jaroslaw; Fabien, Vincent; Filippatos, Gerasimos; Haboubi, Teba; Keren, Andre; Nicolau, José Carlos 
Source: European journal of heart failure. Unidade: FM
Subjects: INSUFICIÊNCIA CARDÍACA, DOENÇAS NUTRICIONAIS E METABÓLICAS, FERRO, COMPOSTOS INORGÂNICOS, HOSPITALIZAÇÃO, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO, RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PONIKOWSKI, Piotr et al. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure. European journal of heart failure, v. 21, n. 12, p. 1651-1658, 2019Tradução . . Disponível em: https://doi.org/10.1002/ejhf.1710. Acesso em: 16 nov. 2024.APA
Ponikowski, P., Kirwan, B. -A., Anker, S. D., Dorobantu, M., Drozdz, J., Fabien, V., et al. (2019). Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure. European journal of heart failure, 21( 12), 1651-1658. doi:10.1002/ejhf.1710NLM
Ponikowski P, Kirwan B-A, Anker SD, Dorobantu M, Drozdz J, Fabien V, Filippatos G, Haboubi T, Keren A, Nicolau JC. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure [Internet]. European journal of heart failure. 2019 ; 21( 12): 1651-1658.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1002/ejhf.1710Vancouver
Ponikowski P, Kirwan B-A, Anker SD, Dorobantu M, Drozdz J, Fabien V, Filippatos G, Haboubi T, Keren A, Nicolau JC. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure [Internet]. European journal of heart failure. 2019 ; 21( 12): 1651-1658.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1002/ejhf.1710
